The President Donald Trump administration's request for Novavax Inc. to conduct new clinical trials for its COVID-19 vaccine has created uncertainty across the vaccine industry, potentially affecting ...

The Trump administration’s effort to impose new requirements on Novavax’s COVID-19 vaccine — the nation’s only traditional protein-based option for the coronavirus — is sowing uncert ...

At the insistence of Justice Neil Gorsuch, she withdrew the allegation that the other side had lied but held firm to the ...

“Mexico has committed to make an immediate transfer of water from international reservoirs and increase the U.S. share of the ...

Kennedy won Senate confirmation to his job, in part, by promising not to change the nation’s vaccine schedule. Since taking ...

Novavax is working with the FDA to meet additional requirements and hopes to secure full approval as soon as possible.

‘Many failures’: FDA whistleblower spills on DEI and bad practices during Biden administration Fox News Digital spoke to former FDA official David Oliveira about the FDA’s tobacco chief ...

Novavax has not received an official response from the FDA related to the status of the BLA. The BLA was based on data from a phase III study, which showed the vaccine was safe and effective for ...

When asked if the delay resulted from "personnel being shuffled" at the FDA, Kennedy attributed it to the vaccine's composition. He said Novavax's single antigen approach "has never worked" for ...

By Kamal Choudhury (Reuters) -Vaccine maker Novavax's shares plunged nearly 20% at market close on Thursday, after Health and Human Services Secretary Robert F. Kennedy Jr. raised concerns about ...

This news follows Novavax's announcement last week that it is still awaiting a decision from the FDA regarding its Covid-19 vaccine approval application. Kennedy clarified that the delay in ...